Abbott Labs (NYSE:ABT) is set to report its Q4 2018 earnings on January 23, and we expect the company to post steady growth, primarily led by its Cardiovascular & Neuromodulation, as well as Diagnostics segments. While the Diagnostics business will likely benefit from market share gains in core...
Abbott Labs (NYSE:ABT) is set to report its Q4 2018 earnings on January 23, and we expect the company to post steady growth, primarily led by its Cardiovascular & Neuromodulation, as well as Diagnostics segments. While the Diagnostics business will likely benefit from market share gains in core...
Share this Article
Recommended